STAAR Surgical

STAAR® Surgical Company, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye and delivery systems therefor. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery as an alternative to LASIK is called an Implantable Collamer® Lens or “ICL.” A lens used to replace the natural lens after cataract surgery is called an intraocular lens or “IOL.” Over 500,000 Visian ICLs have been implanted to date; to learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 300 full time employees and markets lenses in over 70 countries. Headquartered in Monrovia, CA, conducts operations in the following locations: Nidau, Switzerland; Ichikawa City, Japan; Aliso Viejo, CA; and Monrovia, CA.
Company Growth (employees)
Type
Public
HQ
Monrovia, US
Founded
1982
Size (employees)
336 (est)
Website
staar.com
STAAR Surgical was founded in 1982 and is headquartered in Monrovia, US

STAAR Surgical Office Locations

STAAR Surgical has offices in Monrovia, Nidau and Tustin
Monrovia, US (HQ)
1911 Walker Ave
Nidau, CH
104 Hauptstrasse

STAAR Surgical Data and Metrics

STAAR Surgical Financial Metrics

STAAR Surgical's revenue was reported to be $20.4 m in Q1, 2017
USD

Revenue (Q1, 2017)

20.4 m

Gross profit (Q1, 2017)

14.6 m

Gross profit margin (Q1, 2017), %

72%

Net income (Q1, 2017)

(2.2 m)

EBIT (Q1, 2017)

(2.1 m)

Market capitalization (17-Aug-2017)

474.8 m

Cash (31-Mar-2017)

13.5 m
STAAR Surgical's current market capitalization is $474.8 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

72.2 m75 m77.1 m82.4 m

Revenue growth, %

4%3%7%

Cost of goods sold

21.9 m26.2 m24.4 m24.1 m

Gross profit

50.3 m48.8 m52.7 m58.4 m

Gross profit Margin, %

70%65%68%71%

R&D expense

20.3 m

General and administrative expense

22.3 m

Operating expense total

42.5 m

EBIT

700 k(8 m)(5.3 m)(12.7 m)

EBIT margin, %

1%(11%)(7%)(15%)

Interest expense

170 k154 k128 k115 k

Interest income

59 k51 k50 k3 k

Income tax expense

716 k(253 k)928 k(315 k)

Net Income

398 k(8.4 m)(6.5 m)(12.1 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

20 m18.2 m18.9 m18.7 m18.8 m19.3 m21 m20.1 m20.4 m

Cost of goods sold

6.4 m6.3 m6 m6.3 m6 m6.3 m6.3 m5.2 m5.8 m

Gross profit

13.7 m11.9 m12.9 m12.4 m12.8 m13 m14.6 m14.9 m14.6 m

Gross profit Margin, %

68%65%68%66%68%67%70%74%72%

R&D expense

2.5 m3.1 m3.6 m3.5 m3.7 m6.9 m4.7 m4.5 m4.8 m

General and administrative expense

5.3 m3.3 m5.1 m4.7 m4.9 m8.5 m4.9 m5 m5.4 m

Operating expense total

7.8 m6.4 m8.7 m8.3 m8.5 m15.4 m9.6 m9.4 m10.1 m

EBIT

(1.4 m)(1.6 m)(1.5 m)(1.7 m)(2 m)(10.1 m)(2.1 m)(1.7 m)(2.1 m)

EBIT margin, %

(7%)(9%)(8%)(9%)(11%)(52%)(10%)(9%)(10%)

Interest expense

(34 k)(35 k)(36 k)(33 k)(29 k)(28 k)(29 k)(29 k)(28 k)

Interest income

10 k7 k49 k1 k

Pre tax profit

(1.4 m)(1.8 m)(2.3 m)(1.7 m)

Income tax expense

367 k548 k(28 k)153 k(11 k)(1.6 m)(131 k)71 k141 k

Net Income

(1.8 m)(2.7 m)(2.3 m)(1.6 m)(1.8 m)(8 m)(2.1 m)(1.8 m)(2.2 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

23 m13 m13.4 m14 m

Accounts Receivable

10.7 k11.1 k15.7 k16.3 k

Inventories

12.5 k15.7 k15.9 k14.8 m

Current Assets

50.1 m44.9 m49.1 m49.9 m

PP&E

7.4 m10.1 m10.1 m11.8 m

Goodwill

1.8 m1.8 m1.8 m1.8 m

Total Assets

61.9 m58.9 m63 m65.4 m

Accounts Payable

6.3 m6.6 m6.7 m8.3 m

Total Debt

4.3 m

Current Liabilities

18.4 m16.4 m17.9 m21.1 m

Total Liabilities

27.5 m

Additional Paid-in Capital

170.2 m178.2 m187 m197.7 m

Retained Earnings

(132.1 m)(140.4 m)(147 m)(159.1 m)

Total Equity

38.9 m37.1 m38.8 m37.9 m

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.6 x1.6 x1.6 x1.7 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

19.2 m18.4 m10.8 m15.3 m16.1 m9 m12.7 m14.3 m13.5 m

Inventories

14.9 m15.7 m15.3 m14.2 m14.6 m16 m15.7 m15.9 m14.6 m

Current Assets

50.7 m49.4 m43 m46.6 m48.1 m46.2 m48.9 m49.7 m49 m

PP&E

9.3 m9.3 m9.9 m9.9 m9.9 m11 m11.4 m11.7 m12.1 m

Goodwill

1.8 m1.8 m1.8 m1.8 m1.8 m1.8 m1.8 m1.8 m1.8 m

Total Assets

64.4 m62.8 m56.8 m60.3 m61.9 m61.9 m65.3 m66.3 m65.4 m

Accounts Payable

5.3 m6.3 m4.9 m4.8 m5.8 m6.9 m8.7 m8 m7.6 m

Current Liabilities

17.2 m17 m15 m15 m16.9 m18 m20.4 m21.3 m21.8 m

Additional Paid-in Capital

176.2 m178 m179.8 m185 m186.3 m194 m195.1 m196.4 m198.6 m

Retained Earnings

(135.2 m)(137.9 m)(142.8 m)(144.4 m)(146.1 m)(155 m)(157.2 m)(158.9 m)(161.3 m)

Total Equity

39.8 m39.5 m38.3 m38 m37.7 m37 m

Financial Leverage

1.5 x1.6 x1.6 x1.7 x1.8 x1.8 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

398 k(8.4 m)(6.5 m)(12.1 m)

Depreciation and Amortization

1.7 m2.1 m2.2 m2.7 m

Accounts Receivable

(2.9 m)(934 k)(5 m)(771 k)

Inventories

(1.6 m)(3.9 m)327 k1.8 m

Accounts Payable

367 k972 k14 k1 m

Cash From Operating Activities

3.4 m(9.9 m)389 k1 m

Purchases of PP&E

(3.4 m)(4.1 m)(2 m)(3.2 m)

Cash From Investing Activities

(3.4 m)(4.1 m)(2 m)(3.2 m)

Cash From Financing Activities

2.4 m2.5 m4.6 m3 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(1.8 m)(2.7 m)(2.3 m)(1.6 m)(1.8 m)(8 m)(2.1 m)(1.8 m)(2.2 m)

Accounts Payable

5.3 m6.3 m4.9 m4.8 m5.8 m6.9 m8.7 m8 m7.6 m
USDY, 2017

Revenue/Employee

60.6 k

Financial Leverage

1.8 x

STAAR Surgical Operating Metrics

FY, 2016

Patents Issued

67

Patents Pending

20

Trademarks

11

STAAR Surgical Market Value History

STAAR Surgical Revenue Breakdown

STAAR Surgical Job Categories

Traffic Overview of STAAR Surgical

STAAR Surgical Online and Social Media Presence

STAAR Surgical Company Life and Culture

You may also be interested in